EP1542972A4 - Cyclooxygenase- 2 selective inhibitors, compositions and methods of use - Google Patents

Cyclooxygenase- 2 selective inhibitors, compositions and methods of use

Info

Publication number
EP1542972A4
EP1542972A4 EP03772004A EP03772004A EP1542972A4 EP 1542972 A4 EP1542972 A4 EP 1542972A4 EP 03772004 A EP03772004 A EP 03772004A EP 03772004 A EP03772004 A EP 03772004A EP 1542972 A4 EP1542972 A4 EP 1542972A4
Authority
EP
European Patent Office
Prior art keywords
cyclooxygenase
compositions
methods
selective inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03772004A
Other languages
German (de)
French (fr)
Other versions
EP1542972A2 (en
Inventor
David S Garvey
Subhash P Khanapure
Ramani R Ranatunge
Stewart K Richardson
Joseph D Schroeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of EP1542972A2 publication Critical patent/EP1542972A2/en
Publication of EP1542972A4 publication Critical patent/EP1542972A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
EP03772004A 2002-07-29 2003-07-29 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use Withdrawn EP1542972A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39882902P 2002-07-29 2002-07-29
US398829P 2002-07-29
PCT/US2003/023605 WO2004010945A2 (en) 2002-07-29 2003-07-29 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use

Publications (2)

Publication Number Publication Date
EP1542972A2 EP1542972A2 (en) 2005-06-22
EP1542972A4 true EP1542972A4 (en) 2008-01-23

Family

ID=31188498

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03772004A Withdrawn EP1542972A4 (en) 2002-07-29 2003-07-29 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use

Country Status (6)

Country Link
US (2) US7244753B2 (en)
EP (1) EP1542972A4 (en)
JP (1) JP2005538110A (en)
AU (1) AU2003261281A1 (en)
CA (1) CA2493156A1 (en)
WO (1) WO2004010945A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (en) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES
CA2393724A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
AU2003247622A1 (en) * 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003252515A1 (en) * 2002-07-26 2004-02-16 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
JP4425921B2 (en) * 2003-03-05 2010-03-03 メルク フロスト カンパニー Nitrogen oxide releasing prodrug of diaryl 2- (5H) -furanone acting as cyclooxygenase-2 inhibitor
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
JO3215B1 (en) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy
JPWO2014163142A1 (en) * 2013-04-03 2017-02-16 国立大学法人愛媛大学 Ophthalmic composition
RU2690188C2 (en) * 2017-05-26 2019-05-31 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" New multitarget preparation for treating diseases in mammals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010012A1 (en) * 1994-09-29 1996-04-04 The Du Pont Merck Pharmaceutical Company Novel prostaglandin synthase inhibitors
WO1999025695A1 (en) * 1997-11-18 1999-05-27 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238679B (en) 1990-01-29 1993-09-01 Resa Farma OPTICALLY ACTIVE DERIVATIVE OF D-2- (6-METHOXY-2-NAFTIL) ACID - PROPIONIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
GB9200114D0 (en) 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
EP0656881B1 (en) 1992-07-30 1998-10-14 Cal International Limited Ester and combinations of an organic nitrate and a salicylate
IT1256345B (en) 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IT1256450B (en) 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
AU678063B2 (en) 1993-10-06 1997-05-15 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
DK0759899T3 (en) 1994-05-10 1999-12-20 Nicox Sa Nitro compounds and their compositions with anti-inflammatory, analgesic and antithrombotic activities
US5849943A (en) 1994-10-27 1998-12-15 Merck Frosst Canada, Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
IT1274175B (en) 1994-11-22 1997-07-15 Lab Alchemia Srl PROCEDURE FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE CHEMICAL COMBINATION
US5643943A (en) 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5607966A (en) 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6051588A (en) 1995-04-19 2000-04-18 Nitromed Inc Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
DE19515970A1 (en) 1995-05-02 1996-11-07 Bayer Ag Acetylsalicylsäurenitrate
IT1276071B1 (en) 1995-10-31 1997-10-24 Nicox Ltd ANTI-INFLAMMATORY ACTIVITY COMPOSITES
SE9600070D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
KR19990082260A (en) 1996-02-01 1999-11-25 하우드 버나드 Diphenylstilbene as a drug precursor of COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
AU710675B2 (en) 1996-02-01 1999-09-30 Merck Frosst Canada Ltd. Alkylated styrenes as prodrugs to COX-2 inhibitors
IT1282686B1 (en) 1996-02-26 1998-03-31 Nicox Sa COMPOUNDS ABLE TO REDUCE DRUG TOXICITY
ES2182035T3 (en) 1996-03-29 2003-03-01 Merck Frosst Canada Inc DERIVATIVES OF BISARILCICLOBUTENO AS CICLOOXIGENASA INHIBITORS
US7115661B1 (en) 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
IT1288123B1 (en) 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
DE19651243A1 (en) 1996-12-10 1998-06-18 Basf Ag Amphiphilic graft polymers based on graft bases containing N-vinylcarboxamide units, process for their preparation and their use
SE9703693D0 (en) 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
IT1298338B1 (en) 1998-03-05 1999-12-20 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE ULCER
IT1299198B1 (en) 1998-03-05 2000-02-29 Nicox Sa NITRATED SALTS OF ANTI-ULCER DRUGS
SE9802333D0 (en) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
IT1303672B1 (en) 1998-07-28 2001-02-23 Nicox Sa NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS
CA2348741C (en) 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
IT1307928B1 (en) 1999-01-26 2001-11-29 Nicox Sa METHOD OF SYNTHESIS OF NITROXYMETHYLPHENYL ESTERS OF ASPIRINE DERIVATIVES.
IT1308633B1 (en) 1999-03-02 2002-01-09 Nicox Sa NITROSSIDERIVATI.
IT1311923B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311924B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311922B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311921B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
IT1312115B1 (en) 1999-06-24 2002-04-04 Nicox Sa AMORPHOUS COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS
ITMI991517A1 (en) 1999-07-09 2001-01-09 Nicox Sa PROCEDURE FOR OBTAINING EXTERNAL NITROXYMETHYL FENYL OF SALICYLIC ACID DERIVATIVES
IT1313596B1 (en) 1999-08-04 2002-09-09 Nicox Sa PROCESS FOR THE PREPARATION OF NITROXIALKYL ESTERS OF NAPROXENE
IT1314184B1 (en) 1999-08-12 2002-12-06 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS
JP2003531103A (en) 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of c-JUNN-terminal kinase (JNK) and other protein kinases
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
SE0000773D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CA2406947A1 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US20020016342A1 (en) 2000-05-15 2002-02-07 Edward Scolnick Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2001093680A1 (en) 2000-06-02 2001-12-13 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
SE0002476D0 (en) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
IT1318673B1 (en) 2000-08-08 2003-08-27 Nicox Sa DRUGS FOR SEXUAL DYSFUNCTIONS.
IT1318674B1 (en) 2000-08-08 2003-08-27 Nicox Sa DO IT FOR INCONTINENCE.
IT1319202B1 (en) 2000-10-12 2003-09-26 Nicox Sa DRUGS FOR INFLAMMATORY-BASED DISEASES.
IT1320176B1 (en) 2000-12-22 2003-11-26 Nicox Sa SOLID DISPERSIONS OF NITRATED ACTIVE INGREDIENTS.
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
ITMI20010985A1 (en) 2001-05-15 2002-11-15 Nicox Sa DRUGS FOR ALZHEIMER DISEASE
ITMI20011240A1 (en) 2001-06-13 2002-12-13 Nicox Sa DRUGS FOR VASCULOPATHIES
ITMI20011307A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR EPILEPSY
ITMI20011308A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR CHRONIC PAIN
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010012A1 (en) * 1994-09-29 1996-04-04 The Du Pont Merck Pharmaceutical Company Novel prostaglandin synthase inhibitors
WO1999025695A1 (en) * 1997-11-18 1999-05-27 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICOLAUS B J R: "Symbiotic Approach to Drug Design", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), pages 173 - 186, XP002197412 *

Also Published As

Publication number Publication date
AU2003261281A1 (en) 2004-02-16
JP2005538110A (en) 2005-12-15
WO2004010945A2 (en) 2004-02-05
US7244753B2 (en) 2007-07-17
CA2493156A1 (en) 2004-02-05
WO2004010945A3 (en) 2004-04-22
US20070238735A1 (en) 2007-10-11
EP1542972A2 (en) 2005-06-22
US20040072883A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
EP1534683A4 (en) Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003303128A8 (en) Inhibitors and methods of use thereof
IL164703A0 (en) ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
EG27049A (en) P38 inhibitors and methods of use thereof
AU2003259735A8 (en) Small-mer compositions and methods of use
HK1080069A1 (en) Nitrooxyderivatives of cyclooxygenase-2 inhibitors
AU2003291668A8 (en) Sacrificial compositions, methods of use thereof, and methods of decomposition thereof
PL378432A1 (en) P38 inhibitors and methods of use thereof
IL176478A0 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
EP1606285A4 (en) Novel ido inhibitors and methods of use
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
HUP0600294A2 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
AU2003239614A8 (en) Cardiolipin compositions, methods of preparation and use
EP1562618A4 (en) Cyclooxygenase-2 inhibitory withanolide compositions and method
AU2003299441A8 (en) Nf-hev compositions and methods of use
EP1663255A4 (en) Withanamide and withanolide compositions and method of use thereof
EP1539134A4 (en) Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1542972A4 (en) Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
PL373523A1 (en) Indol-2-ones as selective inhibitors of cyclooxygenase-2
EP1625141A4 (en) Grp94-based compositions and methods of use thereof
AU2003282593A8 (en) Polyphenolamine composition and method of use
IS2695B (en) Method of container release, and use of that method
GB2394223B (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
EP1638573A4 (en) Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050210

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080102

17Q First examination report despatched

Effective date: 20090429

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NICOX S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101012